fenofibrate has been researched along with Glycogen Storage Disease Type I in 4 studies
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE
Glycogen Storage Disease Type I: An autosomal recessive disease in which gene expression of glucose-6-phosphatase is absent, resulting in hypoglycemia due to lack of glucose production. Accumulation of glycogen in liver and kidney leads to organomegaly, particularly massive hepatomegaly. Increased concentrations of lactic acid and hyperlipidemia appear in the plasma. Clinical gout often appears in early childhood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Glycogen storage disease type Ia (GSD Ia) is caused by autosomal mutations in glucose-6-phosphatase α catalytic subunit (G6PC) and can present with severe hypoglycemia, lactic acidosis and hypertriglyceridemia." | 7.96 | Fenofibrate rapidly decreases hepatic lipid and glycogen storage in neonatal mice with glycogen storage disease type Ia. ( Bay, BH; Kang, HR; Koeberl, DD; Waskowicz, LR; Yavarow, ZA; Yen, PM; Young, SP, 2020) |
| "Glycogen storage disease type Ia (GSD Ia) is caused by autosomal mutations in glucose-6-phosphatase α catalytic subunit (G6PC) and can present with severe hypoglycemia, lactic acidosis and hypertriglyceridemia." | 3.96 | Fenofibrate rapidly decreases hepatic lipid and glycogen storage in neonatal mice with glycogen storage disease type Ia. ( Bay, BH; Kang, HR; Koeberl, DD; Waskowicz, LR; Yavarow, ZA; Yen, PM; Young, SP, 2020) |
| "Because the complications of hyperlipidemia are caused mainly by TC, thereby, by maintaining it at a normal level, we could set a TG target by the linear equation that allowed a certain degree of hypertriglyceridemia." | 1.56 | Lipid status and linear relationship between total cholesterol and triglycerides in glycogen storage disease type I. ( Hong, YH; Ma, MS; Qiu, ZQ; Sun, ZX; Wei, M; Xu, YW; Yuan, YH; Zhang, ZJ, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yavarow, ZA | 1 |
| Kang, HR | 1 |
| Waskowicz, LR | 1 |
| Bay, BH | 1 |
| Young, SP | 1 |
| Yen, PM | 1 |
| Koeberl, DD | 1 |
| Zhang, ZJ | 1 |
| Yuan, YH | 1 |
| Ma, MS | 1 |
| Hong, YH | 1 |
| Sun, ZX | 1 |
| Xu, YW | 1 |
| Wei, M | 1 |
| Qiu, ZQ | 1 |
| Vivatrat, N | 1 |
| Barshop, BA | 1 |
| Jones, KL | 1 |
| Stürmer, T | 1 |
4 other studies available for fenofibrate and Glycogen Storage Disease Type I
| Article | Year |
|---|---|
Fenofibrate rapidly decreases hepatic lipid and glycogen storage in neonatal mice with glycogen storage disease type Ia.
Topics: Acyl-CoA Dehydrogenases; Animals; Animals, Newborn; Autophagosomes; Autophagy; Fatty Acids; Fenofibr | 2020 |
Lipid status and linear relationship between total cholesterol and triglycerides in glycogen storage disease type I.
Topics: Adolescent; Adult; Child; Child, Preschool; Cholesterol; Female; Fenofibrate; Gemfibrozil; Glucose-6 | 2020 |
Severe hypertriglyceridemia and recurrent pancreatitis in a girl with type Ia glycogen storage disease and type III hyperlipoproteinemia.
Topics: Apolipoproteins E; Biopsy; Child, Preschool; Female; Fenofibrate; Glycogen Storage Disease Type I; H | 2009 |
[A case from practice (170). Glycogen storage disease Type I (Von Gierke's disease)].
Topics: Fenofibrate; Glycogen Storage Disease Type I; Humans; Lipids; Male; Middle Aged | 1990 |